Financial Counselors Inc. Has $215,000 Stock Position in Solventum Co. (NYSE:SOLV)

Financial Counselors Inc. lessened its holdings in Solventum Co. (NYSE:SOLV) by 33.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,255 shares of the company’s stock after selling 1,650 shares during the period. Financial Counselors Inc.’s holdings in Solventum were worth $215,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Solventum in the third quarter worth approximately $125,488,000. Boston Partners purchased a new stake in Solventum in the 4th quarter valued at $110,378,000. Point72 Asset Management L.P. bought a new position in Solventum during the 3rd quarter valued at $50,948,000. Nordea Investment Management AB boosted its holdings in Solventum by 189.5% during the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock worth $43,902,000 after acquiring an additional 431,986 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Solventum in the 4th quarter worth $18,583,000.

Analysts Set New Price Targets

Several research analysts recently weighed in on SOLV shares. Piper Sandler boosted their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. Bank of America upped their target price on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Mizuho lifted their price target on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. The Goldman Sachs Group upped their price objective on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Finally, Wells Fargo & Company lifted their target price on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $79.86.

Solventum Trading Down 1.0 %

Shares of Solventum stock opened at $74.78 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The stock has a market capitalization of $12.94 billion and a P/E ratio of 27.19. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The stock’s 50-day simple moving average is $75.51 and its 200 day simple moving average is $71.85.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.